Eurofins Scientific SE's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 53.26.
Eurofins Scientific SE's Days Inventory for the
six
months ended in Dec. 2025 was 0.
Eurofins Scientific SE's Days Payable for the
six
months ended in Dec. 2025 was 0.
Therefore, Eurofins Scientific SE's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 53.26.
Eurofins Scientific SE (OTCPK:ERFSF) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Eurofins Scientific SE Cash Conversion Cycle Related Terms
Eurofins Scientific SE Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Eurofins Scientific SE's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eurofins Scientific SE Cash Conversion Cycle Chart
ERFSF vs TMO, DHR, IDXX: Cash Conversion Cycle Comparison
For the Diagnostics & Research subindustry, Eurofins Scientific SE's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE Cash Conversion Cycle vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's Cash Conversion Cycle falls into.
Eurofins Scientific SE Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Eurofins Scientific SE's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eurofins Scientific SE (ERFSF) has a Cash Conversion Cycle of 53.26 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Eurofins Scientific SE and its competitors.
Is Eurofins Scientific SE's Cash Conversion Cycle too high?
Eurofins Scientific SE's current Cash Conversion Cycle is 53.26. The Medical Diagnostics & Research industry median Cash Conversion Cycle is 73.46. Eurofins Scientific SE's value of 53.26 is 27.5% below this industry median. Overall, Eurofins Scientific SE has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's Cash Conversion Cycle compare to TMO and DHR?
Eurofins Scientific SE's Cash Conversion Cycle of 53.26 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Cash Conversion Cycle is 73.46. Eurofins Scientific SE's value of 53.26 is 27.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Diagnostics & Research company?
The median Cash Conversion Cycle among Medical Diagnostics & Research companies is 73.46, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins Scientific SE's current Cash Conversion Cycle of 53.26 is 27.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Eurofins Scientific SE and its competitors. For the Medical Diagnostics & Research industry, the median Cash Conversion Cycle is 73.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins Scientific SE's current Cash Conversion Cycle is 53.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Fairly Valued. The stock's GF Value™ is $75.93, compared to a current price of $79.77 — trading 5.1% above its estimated fair value. The current Cash Conversion Cycle is 53.26 and 27.5% below the Medical Diagnostics & Research industry median of 73.46. Eurofins Scientific SE's overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current Cash Conversion Cycle is 53.26 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of $79.77 is trading 5.1% above its estimated GF Value™ of $75.93.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for ERFSF:
Cash Conversion Cycle: 53.26
GF Value™: $75.93 vs. price of $79.77 (5.1% above fair value)
Industry Position: 27.5% below the Medical Diagnostics & Research median
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
79GF Score
Get the complete analysis for ERFSF
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 
